Host |
Rabbit |
Klon |
polyclonal+polyclonal+34ßE12 |
Format |
Ready-to-use |
Methode |
P |
Positivkontrolle |
PIN |
Verdünnung |
- |
Isotyp |
Rabbit |
Lokalisation |
p40: NuclearCytokeratin (HMW): CytoplasmicP504S (AMACR): Cytoplasmic |
PIN-5 Cocktail (p40+P504S+Cytokeratin HMW)
|
Diagnostic Biosystems |
polyclonal+polyclonal+34ßE12 |
6 ml |
Ready-to-use |
CE/IVD |
PDR057 |
-
|
Host |
Mouse |
Klon |
ZM385 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Pituitary |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human full-length POU1F1 protein |
Lokalisation |
Nucleus |
PIT1
|
Zeta Corporation |
ZM385 |
1 ml |
Concentrate |
CE/IVD |
Z2676ML |
-
|
Host |
Mouse |
Klon |
ZM385 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Pituitary |
Verdünnung |
- |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human full-length POU1F1 protein |
Lokalisation |
Nucleus |
PIT1
|
Zeta Corporation |
ZM385 |
7 ml |
Concentrate |
CE/IVD |
Z2676MP |
-
|
Host |
Mouse |
Klon |
ZM385 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Pituitary |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human full-length POU1F1 protein |
Lokalisation |
Nucleus |
PIT1
|
Zeta Corporation |
ZM385 |
0.5 ml |
Concentrate |
CE/IVD |
Z2676MS |
-
|
Host |
Mouse |
Klon |
ZM385 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Pituitary |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human full-length POU1F1 protein |
Lokalisation |
Nucleus |
PIT1
|
Zeta Corporation |
ZM385 |
0.1 ml |
Concentrate |
CE/IVD |
Z2676MT |
-
|
Host |
Mouse |
Klon |
ZM161 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Placenta. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant full-length human ALPP protein |
Lokalisation |
Cell membrane |
PLAP
|
Zeta Corporation |
ZM161 |
1.0 ml |
Concentrate |
CE/IVD |
Z2474ML |
-
|
Host |
Mouse |
Klon |
ZM161 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Placenta. |
Verdünnung |
- |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant full-length human ALPP protein |
Lokalisation |
Cell membrane |
PLAP
|
Zeta Corporation |
ZM161 |
7 ml |
Ready-to-use |
CE/IVD |
Z2474MP |
-
|
Host |
Mouse |
Klon |
ZM161 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Placenta. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant full-length human ALPP protein |
Lokalisation |
Cell membrane |
PLAP
|
Zeta Corporation |
ZM161 |
0.5 ml |
Concentrate |
CE/IVD |
Z2474MS |
-
|
Host |
Mouse |
Klon |
ZM161 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Placenta. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant full-length human ALPP protein |
Lokalisation |
Cell membrane |
PLAP
|
Zeta Corporation |
ZM161 |
0.1 ml |
Concentrate |
CE/IVD |
Z2474MT |
-
|
Host |
Rabbit |
Klon |
SP15 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Placenta or Semonima |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Recombinant Protein corresponding to human PLAP |
Lokalisation |
Cell Membrane |
PLAP (Placental Alkaline Phosphatase)
|
Zytomed Systems GmbH |
SP15 |
1 ml |
Concentrate |
RUO |
RBK056 |
-
|
Host |
Rabbit |
Klon |
SP15 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Placenta or Semonima |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Recombinant Protein corresponding to human PLAP |
Lokalisation |
Cell Membrane |
PLAP (Placental Alkaline Phosphatase)
|
Zytomed Systems GmbH |
SP15 |
0.5 ml |
Concentrate |
RUO |
RBK056-05 |
-
|
Host |
Mouse |
Klon |
A16-4 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon |
Verdünnung |
1:25 - 1:100 |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
Recombinant human PMS2 (C-Terminus) |
Lokalisation |
Nucleus |
PMS2
|
Zytomed Systems GmbH |
A16-4 |
0.5 ml |
Concentrate |
RUO |
MSK064-05 |
-
|
Host |
Mouse |
Klon |
A16-4 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Colon |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
Recombinant human PMS2 (C-Terminus) |
Lokalisation |
Nucleus |
PMS2
|
Diagnostic Biosystems |
A16-4 |
6 ml |
Ready-to-use |
CE/IVD |
PDM171 |
-
|
Host |
Rabbit |
Klon |
ZR317 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG |
Verdünnung |
A synthetic peptide corresponding to residues |
Lokalisation |
Nuclear |
PMS2
|
Zeta Corporation |
ZR317 |
1 ml |
Concentrate |
CE/IVD |
Z2621RL |
-
|
Host |
Rabbit |
Klon |
ZR317 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
A synthetic peptide corresponding to residues |
Lokalisation |
Nuclear |
PMS2
|
Zeta Corporation |
ZR317 |
7 ml |
Concentrate |
CE/IVD |
Z2621RP |
-
|
Host |
Rabbit |
Klon |
ZR317 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG |
Verdünnung |
A synthetic peptide corresponding to residues |
Lokalisation |
Nuclear |
PMS2
|
Zeta Corporation |
ZR317 |
0.5 ml |
Concentrate |
CE/IVD |
Z2621RS |
-
|
Host |
Rabbit |
Klon |
ZR317 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG |
Verdünnung |
A synthetic peptide corresponding to residues |
Lokalisation |
Nuclear |
PMS2
|
Zeta Corporation |
ZR317 |
0.1 ml |
Concentrate |
CE/IVD |
Z2621RT |
-
|
Host |
Mouse |
Klon |
3F6 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Infected Lung |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgM |
Lokalisation |
Alveolar Spaces |
Pneumocystis carinii
|
Diagnostic Biosystems |
3F6 |
1 ml |
Concentrate |
CE/IVD |
MOB091 |
-
|
Host |
Mouse |
Klon |
3F6 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Infected Lung |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgM |
Lokalisation |
Alveolar Spaces |
Pneumocystis carinii
|
Diagnostic Biosystems |
3F6 |
0.1 ml |
Concentrate |
CE/IVD |
MOB091-01 |
-
|
Host |
Mouse |
Klon |
3F6 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Infected Lung |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgM |
Lokalisation |
Alveolar Spaces |
Pneumocystis carinii
|
Diagnostic Biosystems |
3F6 |
0.5 ml |
Concentrate |
CE/IVD |
MOB091-05 |
-
|
Host |
Mouse |
Klon |
3F6 |
Format |
ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Infected Lung |
Verdünnung |
--- |
Isotyp |
Mouse IgM |
Lokalisation |
Alveolar Spaces |
Pneumocystis carinii
|
Diagnostic Biosystems |
3F6 |
6 ml |
ready-to-use |
CE/IVD |
PDM584 |
-
|
Host |
Mouse |
Klon |
D2-40 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Germ cell tumor. |
Verdünnung |
1:20 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
M2A |
Lokalisation |
Cytoplasm |
Podoplanin
|
Zeta Corporation |
D2-40 |
1.0 ml |
Concentrate |
CE/IVD |
Z2097ML |
-
|
Host |
Mouse |
Klon |
D2-40 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Germ cell tumor. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
M2A |
Lokalisation |
Cytoplasm |
Podoplanin
|
Zeta Corporation |
D2-40 |
7 ml |
Ready-to-use |
CE/IVD |
Z2097MP |
-
|
Host |
Mouse |
Klon |
D2-40 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Germ cell tumor. |
Verdünnung |
1:20 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
M2A |
Lokalisation |
Cytoplasm |
Podoplanin
|
Zeta Corporation |
D2-40 |
0.5 ml |
Concentrate |
CE/IVD |
Z2097MS |
-
|
Host |
Mouse |
Klon |
D2-40 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Germ cell tumor. |
Verdünnung |
1:20 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
M2A |
Lokalisation |
Cytoplasm |
Podoplanin
|
Zeta Corporation |
D2-40 |
0.1 ml |
Concentrate |
CE/IVD |
Z2097MT |
-
|
Host |
Mouse |
Klon |
D2-40 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Lymphendothelium |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Podoplanin (Lymphatic endothelium marker)
|
Diagnostic Biosystems |
D2-40 |
6 ml |
Ready-to-use |
CE/IVD |
PDM558 |
-
|
Host |
Mouse |
Klon |
D2-40 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Lymphendothelium |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Podoplanin (Lymphatic endothelium marker)
|
Diagnostic Biosystems |
D2-40 |
25 ml |
Ready-to-use |
CE/IVD |
PDM558-25 |
-
|
Host |
Monospecific Mouse |
Klon |
ZM31 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Mesothelioma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human Podoplanin (PDPN) protein fragment (around aa 24-126) |
Lokalisation |
Cytoplasm |
Podoplanin (Lymphatic endothelium marker)
|
Zeta Corporation |
ZM31 |
1 ml |
Concentrate |
CE/IVD |
Z2338ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM31 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Mesothelioma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human Podoplanin (PDPN) protein fragment (around aa 24-126) |
Lokalisation |
Cytoplasm |
Podoplanin (Lymphatic endothelium marker)
|
Zeta Corporation |
ZM31 |
7 ml |
Ready-to-use |
CE/IVD |
Z2338MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM31 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Mesothelioma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human Podoplanin (PDPN) protein fragment (around aa 24-126) |
Lokalisation |
Cytoplasm |
Podoplanin (Lymphatic endothelium marker)
|
Zeta Corporation |
ZM31 |
0.5 ml |
Concentrate |
CE/IVD |
Z2338MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM31 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Mesothelioma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human Podoplanin (PDPN) protein fragment (around aa 24-126) |
Lokalisation |
Cytoplasm |
Podoplanin (Lymphatic endothelium marker)
|
Zeta Corporation |
ZM31 |
0.1 ml |
Concentrate |
CE/IVD |
Z2338MT |
-
|
Host |
Rabbit |
Klon |
EPR20330 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma, testis |
Verdünnung |
1:100 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment within Human PRAME aa 100 to the C-terminus. The exact sequence is proprietary. |
Lokalisation |
Nucleus, cell membrane |
PRAME
|
Biocare Medical |
EPR20330 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3252A |
-
|
Host |
Rabbit |
Klon |
EPR20330 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma, testis |
Verdünnung |
1:100 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment within Human PRAME aa 100 to the C-terminus. The exact sequence is proprietary. |
Lokalisation |
Nucleus, cell membrane |
PRAME
|
Biocare Medical |
EPR20330 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3252B |
-
|
Host |
Rabbit |
Klon |
EPR20330 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment within Human PRAME aa 100 to the C-terminus. The exact sequence is proprietary. |
Lokalisation |
Nucleus, cell membrane |
PRAME
|
Biocare Medical |
EPR20330 |
7 ml |
Ready-to-use |
CE/IVD |
ALI3252G7 |
-
|
Host |
Rabbit |
Klon |
EPR20330 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment within Human PRAME aa 100 to the C-terminus. The exact sequence is proprietary. |
Lokalisation |
Nucleus, cell membrane |
PRAME
|
Biocare Medical |
EPR20330 |
6 ml |
Ready-to-use |
CE/IVD |
API3252AA |
-
|
Host |
Rabbit |
Klon |
EPR20330 |
Format |
ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Nucleus, Cytoplasma membrane |
PRAME
|
Zytomed Systems GmbH |
EPR20330 |
6 ml |
ready-to-use |
RUO |
RBG073 |
-
|
Host |
Rabbit |
Klon |
EPR20330 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Nucleus, Cytoplasma membrane |
PRAME
|
Zytomed Systems GmbH |
EPR20330 |
0.5 ml |
Concentrate |
RUO |
RBK073-05 |
-
|
Host |
Rabbit |
Klon |
EPR20330 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment within Human PRAME aa 100 to the C-terminus. The exact sequence is proprietary. |
Lokalisation |
Nucleus, cell membrane |
PRAME
|
Diagnostic Biosystems |
EPR20330 |
1 ml |
Concentrate |
CE/IVD |
RMAB109 |
-
|
Host |
Rabbit |
Klon |
EPR20330 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment within Human PRAME aa 100 to the C-terminus. The exact sequence is proprietary. |
Lokalisation |
Nucleus, cell membrane |
PRAME
|
Diagnostic Biosystems |
EPR20330 |
0.1 ml |
Concentrate |
CE/IVD |
RMAB109-01 |
-
|
Host |
Rabbit |
Klon |
EPR20330 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment within Human PRAME aa 100 to the C-terminus. The exact sequence is proprietary. |
Lokalisation |
Nucleus, cell membrane |
PRAME
|
Diagnostic Biosystems |
EPR20330 |
0.5 ml |
Concentrate |
CE/IVD |
RMAB109-05 |
-
|
Host |
Rabbit |
Klon |
EPR20330 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment within Human PRAME aa 100 to the C-terminus. The exact sequence is proprietary. |
Lokalisation |
Nucleus, cell membrane |
PRAME
|
Diagnostic Biosystems |
EPR20330 |
6 ml |
Ready-to-use |
CE/IVD |
RMPD109 |
-
|
Host |
Mouse |
Klon |
2G11 |
Format |
Purified |
Methode |
EL, P |
Vorbehandlung |
Citrate |
Isotyp |
Mouse IgG2a |
Verdünnung |
Synthetic peptide 146-R (154) R (171) -182 of ovine PrP |
Prion Protein (PrP, CD230)
|
Zytomed Systems GmbH |
2G11 |
250 µg |
Purified |
RUO |
616-0195 |
-
|
Host |
Rabbit |
Klon |
SP2 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA pH8 |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:25 -1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Nucleus |
Progesterone Receptor
|
Diagnostic Biosystems |
SP2 |
1 ml |
Concentrate |
CE/IVD |
RMAB002 |
-
|
Host |
Rabbit |
Klon |
SP2 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA pH8 |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Nucleus |
Progesterone Receptor
|
Diagnostic Biosystems |
SP2 |
0.1 ml |
Concentrate |
CE/IVD |
RMAB002-01 |
-
|
Host |
Rabbit |
Klon |
SP2 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA pH8 |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Nucleus |
Progesterone Receptor
|
Diagnostic Biosystems |
SP2 |
0.5 ml |
Concentrate |
CE/IVD |
RMAB002-05 |
-
|
Host |
Rabbit |
Klon |
SP2 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
EDTA pH8 |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Nucleus |
Progesterone Receptor
|
Diagnostic Biosystems |
SP2 |
6 ml |
Ready-to-use |
CE/IVD |
RMPD002 |
-
|
Host |
Rabbit |
Klon |
ZR4 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Breast carcinomas. |
Verdünnung |
1:200 - 1:400 |
Isotyp |
IgG |
Verdünnung |
Recombinant protein encoding human progesterone receptor 412-526 aa |
Lokalisation |
Nucleus |
Progesterone Receptor
|
Zeta Corporation |
ZR4 |
1.0 ml |
Concentrate |
CE/IVD |
Z2023RL |
-
|
Host |
Rabbit |
Klon |
ZR4 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Breast carcinomas. |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant protein encoding human progesterone receptor 412-526 aa |
Lokalisation |
Nucleus |
Progesterone Receptor
|
Zeta Corporation |
ZR4 |
7 ml |
Ready-to-use |
CE/IVD |
Z2023RP |
-
|
Host |
Rabbit |
Klon |
ZR4 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Breast carcinomas. |
Verdünnung |
1:200 - 1:400 |
Isotyp |
IgG |
Verdünnung |
Recombinant protein encoding human progesterone receptor 412-526 aa |
Lokalisation |
Nucleus |
Progesterone Receptor
|
Zeta Corporation |
ZR4 |
0.5 ml |
Concentrate |
CE/IVD |
Z2023RS |
-
|
Host |
Rabbit |
Klon |
ZR4 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Breast carcinomas. |
Verdünnung |
1:200 - 1:400 |
Isotyp |
IgG |
Verdünnung |
Recombinant protein encoding human progesterone receptor 412-526 aa |
Lokalisation |
Nucleus |
Progesterone Receptor
|
Zeta Corporation |
ZR4 |
0.1 ml |
Concentrate |
CE/IVD |
Z2023RT |
-
|